Pharmafile Logo
Pharmafocus logo
Advanced Search

Sales and Marketing

Showing 15 posts of 11527 posts found.

Samsung Bioepis takes AbbVie to court over attempts to delay Humira biosimilars

April 5, 2016 Manufacturing and Production, Research and Development, Sales and Marketing AbbVie, Biogen, Humira, Samsung Bioepis, biosimilars, rheumatoid arthritis

Samsung Bioepis has filed a lawsuit against Abbvie (NYSE: ABBV) to stop the maker of the world’s bestselling drug Humira …
News

Gilead to buy Nimbus Therapeutics’ unit, trial drug for up to $1.2 billion

April 5, 2016 Manufacturing and Production, Research and Development, Sales and Marketing Gilead Sciences, M&A, MA, Nimbus Apollo, Nimbus Therapeutics, merger and acquisitions

Gilead Sciences (Nasdaq: GILD) has agreed to buy a unit of biotechnology firm Nimbus Therapeutics and its trial drug to …
News

Janssen and Genmab sued for patent infringement in US

April 5, 2016 Manufacturing and Production, Research and Development, Sales and Marketing Genmab, Janssen, darzalex, morphosys, patent infringement

German biotech company, Morphosys, is suing Janssen and Genmab for alleged patent infringement in their oncology drug, Darzalex (daratumumab).
News

Anika Therapeutics names CMO, COO

April 4, 2016 Sales and Marketing Anika Therapeutics, CMO, COO, Executive appointment

Anika Therapeutics (Nasdaq: ANIK) on Monday named the executive appointments of Stephen Mascioli the chief medical officer (CMO) and Dana …
Appointment

Eisai’s Halaven recommended for European approval

April 4, 2016 Research and Development, Sales and Marketing Eisai, Halaven, liposarcoma

Eisai has received a positive opinion from the European Commission’s CHMP for Halaven (eribulin) as a second-line therapy for patients …
News

Weekly Movers: Lupin, Natco Pharma, Keryx, Puma Biotech

April 4, 2016 Research and Development, Sales and Marketing

Another week of big gains and some major losses has come to pass. While the Indian pharma sector continues to …
Feature

Research shows Novartis’s Entresto reduces cardiovascular death and heart failure

April 4, 2016 Research and Development, Sales and Marketing Entresto, Novartis, Regeneron, Sanofi, cardiovascular, clinical trial, patent

Novartis has announced results from the PARADIGM-HF clinical trial that show that Entresto (sacubitril/valsartan) consistently demonstrated benefit among heart failure …
News

Takeda, Teva name Hiroshi Matsumori CEO of Japanese generic drug joint venture

April 4, 2016 Business Services, Sales and Marketing CEO Appointment, Takeda, Teva, joint venture

Japanese drug firm Takeda (TYO: 4502) and Israel-based Teva (NYSE: TEVA) named Hiroshi Matsumori the chief executive for their newly-formed …
Appointment

Amicus Therapeutics’ Fabry disease drug gets European regulatory support

April 4, 2016 Research and Development, Sales and Marketing Amicus Therapeutics, EMA, Fabry disease, genetic disorder, rare disease

Shares in biotechnology firm Amicus Therapeutics (Nasdaq: FOLD) rose to close up nearly 3% after the European regulators announced backing …
News

Amgen’s high cholesterol drug at centre of patent court case yields positive clinical trial results

April 4, 2016 Research and Development, Sales and Marketing Amgen, Repatha, Sanofi, high cholesterol. ldl, ldl-c, phase III, statins

Amgen has announced positive results from the Phase III GAUSS-3 clinical trial evaluating Repatha (evolucumab) in patients with high cholesterol …
News

GSK’s gene therapy for rare condition in children gets EMA backing

April 4, 2016 Research and Development, Sales and Marketing ADA-SCID, European Medicines Agency, GlaxoSmithKline, Orphan Therapy, Rare Treatment, drug trial, gene therapy

UK drug major GlaxoSmithKline (LSE: GSK) has won marketing recommendation from European regulators for its first gene therapy to treat …
News

Timeline of turmoil – Valeant Pharmaceuticals’ troubled March 2016

April 4, 2016 Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Share price, Valeant, fall, month from hell, timeline, turmoil

As far as months go, March 2016 couldn’t have gone much worse for Valeant Pharmaceuticals. The Canada-based company has been …
Feature

Two CHMP nods for Janssen

April 4, 2016 Research and Development, Sales and Marketing Xeplion, darzalex, multiple myeloma

The European Commission’s scientific committee has recommended Janssen’s Darzalex (daratumumab) for multiple myeloma and Trevicta (paliperidone palmitate) for maintenance treatment …
News

Sanofi’s dengue vaccine rolled out for world’s first public immunisation program

April 4, 2016 Sales and Marketing Philippines, Sanofi, Vaccine, children, dengue, dengvaxia, immunisation, prevention, public health

Sanofi, along with its vaccines global business unit Sanofi Pasteur, has announced the beginning of the first public dengue immunisation …
News

Pfizer’s cholesterol-lowering bococizumab shows promise in Phase III trials

April 1, 2016 Research and Development, Sales and Marketing Pfizer, bococizumab, lipid, phase 3, phase III, spire, spire-ai

Pfizer (NYSE: PFE) has announced positive top line results from the SPIRE-AI Phase III clinical trial evaluating bococizumab. This protein …
News
The Gateway to Local Adoption Series

Latest content

Major funding opportunity opens for early cancer diagnostics

September 4, 2026

Androlabs receives UK authorisation for new Testavan presentation

September 4, 2026

CEPI backs African-led Bundibugyo Ebola vaccine development

September 3, 2026

Cytomos appoints life sciences executive to board

September 2, 2026

Cell therapy partnership aims to bring liver disease treatment closer to US patients

September 1, 2026